Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal.
about
Human pluripotent stem cells for modelling human liver diseases and cell therapyQuality assessment of the genetic test for familial hypercholesterolemia in the Netherlands.Efficacy and safety of proprotein convertase subtilisin/kexin type 9 monoclonal antibody in adults with familial hypercholesterolemiaEfficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies.Cascade Screening for Familial Hypercholesterolemia (FH)No significant improvement of cardiovascular disease risk indicators by a lifestyle intervention in people with familial hypercholesterolemia compared to usual care: results of a randomised controlled trialFounder mutations in the Netherlands: geographical distribution of the most prevalent mutations in the low-density lipoprotein receptor and apolipoprotein B genesLong-term statin treatment in children with familial hypercholesterolemia: more insight into tolerability and adherence.Plasma levels of PCSK9 and phenotypic variability in familial hypercholesterolemia.Improved access to life insurance after genetic diagnosis of familial hypercholesterolaemia: cross-sectional postal questionnaire study.Targeted next-generation sequencing to diagnose disorders of HDL cholesterol.Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher.ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemiaInheritance pattern of familial hypercholesterolemia and markers of cardiovascular risk.Molecular pathology of familial hypercholesterolemia, related dyslipidemias and therapies beyond the statins.Risk stratification in cardiovascular disease primary prevention - scoring systems, novel markers, and imaging techniques.Efficacy and safety of mipomersen sodium (Kynamro).Screening methods in the diagnosis and assessment of children and adolescents with familial hypercholesterolemia.Management of hypercholesterolemia in children.Public health and precision medicine share a goal.A Systematic Review of Cardiovascular Outcomes-Based Cost-Effectiveness Analyses of Lipid-Lowering Therapies.Assessment of physicians' awareness and knowledge of familial hypercholesterolemia in Saudi Arabia: Is there a gap?Familial hypercholesterolemia in Chinese patients with premature ST-segment-elevation myocardial infarction: Prevalence, lipid management and 1-year follow-up.Therapeutic potential of mipomersen in the management of familial hypercholesterolaemia.European guidelines on cardiovascular disease prevention in clinical practice (version 2012) : the fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituteEuropean Guidelines on cardiovascular disease prevention in clinical practice (version 2012): the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constitutedCurrent novel-gene-finding strategy for autosomal-dominant hypercholesterolaemia needs refinement.Spectrum of low-density lipoprotein receptor (LDLR) mutations in a cohort of Sri Lankan patients with familial hypercholesterolemia - a preliminary report.How do the experiences and beliefs of adults and children with heterozygous familial hypercholesterolaemia influence their adherence to treatment? A systematic review of qualitative evidence protocol
P2860
Q27005360-AA2C16DA-70C3-40DA-8112-B7B4926CBAF4Q30541806-346F4713-B8B1-4785-8625-BAC69962DA4CQ33728343-EAF756FC-7E77-4973-BF50-01A7CE6908AFQ33818871-545F1DBB-1D67-495C-8673-972CEC8B7482Q33919782-3A0ABCC8-B086-48C7-8B5A-F4653BEF828DQ34227238-4CC739F2-EBE7-4D81-84CF-A99E96A0321FQ34679770-A4799DC8-9048-435A-B91A-1BDFD125B2D7Q35214678-19559595-9C5D-49D4-984F-F1401F7571ECQ35897064-F0061EC2-6C95-4958-A054-C1BF7DC54C4EQ36035727-E9AD8428-DB12-4CC2-8846-87EE0C8C94CAQ36093235-E66F2D6F-E2BA-4427-A3A2-415977B748C8Q36130225-45D8433D-0997-40DE-B3B3-E32459D06C0DQ36278291-25394063-F2AE-41AE-B554-4080A93C8924Q37076534-6B8B0074-6D61-4B02-B27D-8A3A448CD84BQ37972887-B97E5EA1-5BAD-4649-A1C8-A0CD4C9689F8Q37973386-6FBE606F-FC85-43B2-AC3D-F5D621C01B28Q38101125-AD2E7AC4-628D-40AF-8DDA-9490190B3825Q38132257-7064D27D-B3E3-4F26-89D5-7E057C2AB0DCQ38175366-99C65420-4DAC-4066-ACE2-004C3BB80B1EQ38918818-20EE2CA1-A5BF-4BD1-AC51-6A6F305CCD95Q38992196-EB5893EF-1E8F-4962-BFD2-04690DF6D3D9Q41444737-D4B5B8EC-F442-4389-93B2-C2360EA719A9Q43067844-9DCB2AC1-4CD7-47D5-9856-46E187772EB2Q47380672-82D33EE5-C8D1-4E03-B7D6-9153EE8D2611Q48525600-60A81246-B8DC-4980-8E10-B3EE9CDF6B74Q48526535-90C472F8-263D-4A9F-90F0-B0E6C9F58FC7Q51033792-120E5C0A-3A3A-48A9-8C4B-F70BB1484DF1Q55021529-AE85DE3C-7BF2-4337-8648-073E889EEDE1Q57169145-88769888-99DC-4740-8399-2769BA60DD20
P2860
Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Two years after molecular diag ...... nority reaches treatment goal.
@ast
Two years after molecular diag ...... nority reaches treatment goal.
@en
Two years after molecular diag ...... nority reaches treatment goal.
@nl
type
label
Two years after molecular diag ...... nority reaches treatment goal.
@ast
Two years after molecular diag ...... nority reaches treatment goal.
@en
Two years after molecular diag ...... nority reaches treatment goal.
@nl
prefLabel
Two years after molecular diag ...... nority reaches treatment goal.
@ast
Two years after molecular diag ...... nority reaches treatment goal.
@en
Two years after molecular diag ...... nority reaches treatment goal.
@nl
P2093
P2860
P1433
P1476
Two years after molecular diag ...... nority reaches treatment goal.
@en
P2093
Barbara A Hutten
Iris Kindt
John J P Kastelein
Maud N Vissers
Roeland Huijgen
Sjoerd B J Verhoeven
P2860
P356
10.1371/JOURNAL.PONE.0009220
P407
P577
2010-02-15T00:00:00Z